Answer:
Scenario: First FDA-approved gene therapy for inherited blindness
When: 2017
Where: United States
Background: Leber congenital amaurosis (LCA) is a rare inherited retinal disease that typically leads to complete blindness in early childhood. In 2017, the FDA approved Luxturna, the first gene therapy to treat inherited vision loss caused by mutations in both copies of the RPE65 gene, which is associated with LCA.
How was gene therapy involved: Luxturna works by replacing the mutated RPE65 gene with a healthy version, using a harmless virus as a vector to deliver the gene to the retina. The treatment involves a one-time injection directly into the eye. The therapy has been shown to improve vision in clinical trials, with some patients gaining the ability to navigate obstacles and even read lines on an eye chart.
Related pictures:
Image of a child with Leber congenital amaurosis before and after treatment with Luxturna.
Schematic representation of the mechanism of gene therapy using a viral vector to deliver the healthy RPE65 gene to the retina.
Photograph of the Luxturna injection being administered to a patient's eye.